Pharma Mar SA · BME:PHM

Pharma Mar SA — Zeltia — CONCORD 2010

21 slides from Pharma Mar SA's conference presentation, Mar 4, 2010

  1. Slide 1: CONCORD 2010: Presentation

    Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview CONCORD 2010: Presentation 4 March 2010 1

  2. Slide 2: Disclaimer

    Disclaimer Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview “This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-

  3. Slide 3: Corporate Overview

    Zetia Corporate Overview

  4. Slide 4: History of Delivering Commercial Success

    History of Delivering Commercial Success Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview Founded in Spain in 1939 and listed Founded: 1939 in 1963. Listed: 1963 Ticker: ZEL SM Holding company with core business in biotechnology. Ma

  5. Slide 5: Strategy & Approach

    oZettia Strategy & Approach

  6. Slide 6: Adopting a Unique Approach to Creating Commercial Value

    Adopting a Unique Approach to Creating Commercial Value Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview The Sea: – Great source of biological material for drug discovery and development – Zeltia’s library includes 85,000 marine sam

  7. Slide 7: Our Human Resources commitments

    Our Human Resources commitments Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview Zeltia’s Total work force To hire Highly-qualified people (by gender aspects) – Over 72% of the Biotech’s employees are PhDs 52% 48% and graduates % of

  8. Slide 8: Success Story: Yondelis

    Success Story: Yondelis Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview Our approach has proven successful: YONDELIS® New marine derived chemical entity with a novel Mechanism of Action EU Marketing Authorisation for 2 indications

  9. Slide 9: Oncology: Yondelis & Pipeline

    Oncology: Yondelis® & Pipeline

  10. Slide 10: Pipeline Yondelis

    Pipeline Yondelis® Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview Soft Tissue Sarcoma (STS) – 2nd/3rd line Relapsed ovarian cancer (Yondelis+Doxil)- 2nd/3rd line Yondelis® STS with translocations-1st line 12.000 treated patients P

  11. Slide 11: Strong Oncology Pipeline

    Strong Oncology Pipeline Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview Relapsed/refractory multiple myeloma Relapsed/refractory Aplidin® T-cell lymphoma 756 treated patients Mielofibrosis Aplidium albicans Combination studies Cer

  12. Slide 12: Forthcoming pivotal trials: Aplidin

    Forthcoming pivotal trials: Aplidin® Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview • Phase II/III pivotal trial in refractory Multiple Myeloma: 2Q010 − 3rd line, in combination with DEXAMETHASONE vs. DEXAMETHASONE − 250 patients

  13. Slide 13: Yondelis: Commercially Driven Licensing Agreements

    Yondelis®: Commercially Driven Licensing Agreements Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Yondelis® Disease Overview 2001: – Licensing agreement initiated with CENTOCOR ORTHO BIOTECH, subsidiary of Johnson & Johnson's 2009: – Licensing ag

  14. Slide 14: Yondelis: Significant Market Potential Unlocked through Regional Specialists

    Yondelis®: Significant Market Potential Unlocked through Regional Specialists Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Yondelis® Disease Overview Western Europe (88% of European market) Sales force: PharmaMar / Innovex (Quintiles) Scandinavi

  15. Slide 15: Alzheimer's Disease and Other Dementias

    Alzheimer’s Disease and Other Dementias

  16. Slide 16: Exciting CNS Pipeline Candidates

    Exciting CNS Pipeline Candidates Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Disease Overview REGULATORY PRECLINICAL DEVELOPMENT CLINICAL DEVELOPMENT TOXICOLOGY NYPTA® (NP-12) p.o. GSK-3 Inhibitor Alzheimer’s Disease NYPTA® (NP-12) p.o.

  17. Slide 17: NYPTA: Transgenic Mice

    NYPTA®: Transgenic Mice Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview Oral chronicle treatment AMYLOID AMYLOIDpathology pathology TAU TAU phosphorylation phosphorylation with NYPTA®: – Significantly reduces the amyloide plaques –

  18. Slide 18: Alzheimer's: High Sales Estimates for Treatment Capable of Retarding Neurodegenerative Process

    Alzheimer’s: High Sales Estimates for Treatment Capable of Retarding Neurodegenerative Process Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview Sales of Alzheimer's Drugs in 2008* Brand Company Generic Class Sales 2008 (m$) +/- (%)

  19. Slide 19: Financial Overview

    oZettia Financial Overview

  20. Slide 20: Focussed on Developing a Strong R&D Programme

    Focussed on Developing a Strong R&D Programme Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview R&D Expenditure – Year on Year Net Revenue by Segment – Year on Year (Euro ‘000) (Euro ‘000) 0 .0 0 11 7 34 00 ,5 .0 0 91 00 57 64 02 ,6

  21. Slide 21: Sales in Biotechnology: national & international

    Sales in Biotechnology: national & international Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview Oncología (Yondelis ®) Diagnostics Kits (CLART®) Sales (Euros) Sales in Spain 3500000 +51% 40.000.000 +58% 3000000 35.000.000 2500000

Zeltia — CONCORD 2010 on 6ix